Could the Ebola virus matrix protein VP40 be a drug target?

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Filoviruses are filamentous lipid-enveloped viruses and include Ebola (EBOV) and Marburg, which are morphologically identical but antigenically distinct. These viruses can be very deadly with outbreaks of EBOV having clinical fatality as high as 90%. In 2012 there were two separate Ebola outbreaks in the Democratic Republic of Congo and Uganda that resulted in 25 and 4 fatalities, respectively. The lack of preventive vaccines and FDA-approved therapeutics has struck fear that the EBOV could become a pandemic threat. The Ebola genome encodes only seven genes, which mediate the entry, replication, and egress of the virus from the host cell. The EBOV matrix protein is VP40, which is found localized under the lipid envelope of the virus where it bridges the viral lipid envelope and nucleocapsid. VP40 is effectively a peripheral protein that mediates the plasma membrane binding and budding of the virus prior to egress. A number of studies have demonstrated specific deletions or mutations of VP40 to abrogate viral egress but to date pharmacological inhibition of VP40 has not been demonstrated. This editorial highlights VP40, which is the most abundantly expressed protein of the virus and discusses VP40 as a potential therapeutic target.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalExpert Opinion on Therapeutic Targets
Volume18
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Ebolavirus
Virus Release
Viruses
Disease Outbreaks
Lipids
Democratic Republic of the Congo
Virus Attachment
Nucleocapsid
Uganda
Sequence Deletion
Pandemics
Virus Replication
Pharmaceutical Preparations
Fear
Proteins
Vaccines
Cell Membrane
Genome
Pharmacology
Genes

Keywords

  • Ebola
  • Filamentous virus
  • Lipid-protein interaction
  • Oligomerization
  • Plasma membrane
  • Viral assembly
  • Viral budding
  • Virus
  • VP40

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Could the Ebola virus matrix protein VP40 be a drug target? / Stahelin, Robert.

In: Expert Opinion on Therapeutic Targets, Vol. 18, No. 2, 02.2014, p. 115-120.

Research output: Contribution to journalArticle

@article{e8ed6b0336464b2e9ad93e158f664a30,
title = "Could the Ebola virus matrix protein VP40 be a drug target?",
abstract = "Filoviruses are filamentous lipid-enveloped viruses and include Ebola (EBOV) and Marburg, which are morphologically identical but antigenically distinct. These viruses can be very deadly with outbreaks of EBOV having clinical fatality as high as 90{\%}. In 2012 there were two separate Ebola outbreaks in the Democratic Republic of Congo and Uganda that resulted in 25 and 4 fatalities, respectively. The lack of preventive vaccines and FDA-approved therapeutics has struck fear that the EBOV could become a pandemic threat. The Ebola genome encodes only seven genes, which mediate the entry, replication, and egress of the virus from the host cell. The EBOV matrix protein is VP40, which is found localized under the lipid envelope of the virus where it bridges the viral lipid envelope and nucleocapsid. VP40 is effectively a peripheral protein that mediates the plasma membrane binding and budding of the virus prior to egress. A number of studies have demonstrated specific deletions or mutations of VP40 to abrogate viral egress but to date pharmacological inhibition of VP40 has not been demonstrated. This editorial highlights VP40, which is the most abundantly expressed protein of the virus and discusses VP40 as a potential therapeutic target.",
keywords = "Ebola, Filamentous virus, Lipid-protein interaction, Oligomerization, Plasma membrane, Viral assembly, Viral budding, Virus, VP40",
author = "Robert Stahelin",
year = "2014",
month = "2",
doi = "10.1517/14728222.2014.863877",
language = "English",
volume = "18",
pages = "115--120",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Could the Ebola virus matrix protein VP40 be a drug target?

AU - Stahelin, Robert

PY - 2014/2

Y1 - 2014/2

N2 - Filoviruses are filamentous lipid-enveloped viruses and include Ebola (EBOV) and Marburg, which are morphologically identical but antigenically distinct. These viruses can be very deadly with outbreaks of EBOV having clinical fatality as high as 90%. In 2012 there were two separate Ebola outbreaks in the Democratic Republic of Congo and Uganda that resulted in 25 and 4 fatalities, respectively. The lack of preventive vaccines and FDA-approved therapeutics has struck fear that the EBOV could become a pandemic threat. The Ebola genome encodes only seven genes, which mediate the entry, replication, and egress of the virus from the host cell. The EBOV matrix protein is VP40, which is found localized under the lipid envelope of the virus where it bridges the viral lipid envelope and nucleocapsid. VP40 is effectively a peripheral protein that mediates the plasma membrane binding and budding of the virus prior to egress. A number of studies have demonstrated specific deletions or mutations of VP40 to abrogate viral egress but to date pharmacological inhibition of VP40 has not been demonstrated. This editorial highlights VP40, which is the most abundantly expressed protein of the virus and discusses VP40 as a potential therapeutic target.

AB - Filoviruses are filamentous lipid-enveloped viruses and include Ebola (EBOV) and Marburg, which are morphologically identical but antigenically distinct. These viruses can be very deadly with outbreaks of EBOV having clinical fatality as high as 90%. In 2012 there were two separate Ebola outbreaks in the Democratic Republic of Congo and Uganda that resulted in 25 and 4 fatalities, respectively. The lack of preventive vaccines and FDA-approved therapeutics has struck fear that the EBOV could become a pandemic threat. The Ebola genome encodes only seven genes, which mediate the entry, replication, and egress of the virus from the host cell. The EBOV matrix protein is VP40, which is found localized under the lipid envelope of the virus where it bridges the viral lipid envelope and nucleocapsid. VP40 is effectively a peripheral protein that mediates the plasma membrane binding and budding of the virus prior to egress. A number of studies have demonstrated specific deletions or mutations of VP40 to abrogate viral egress but to date pharmacological inhibition of VP40 has not been demonstrated. This editorial highlights VP40, which is the most abundantly expressed protein of the virus and discusses VP40 as a potential therapeutic target.

KW - Ebola

KW - Filamentous virus

KW - Lipid-protein interaction

KW - Oligomerization

KW - Plasma membrane

KW - Viral assembly

KW - Viral budding

KW - Virus

KW - VP40

UR - http://www.scopus.com/inward/record.url?scp=84892619367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892619367&partnerID=8YFLogxK

U2 - 10.1517/14728222.2014.863877

DO - 10.1517/14728222.2014.863877

M3 - Article

VL - 18

SP - 115

EP - 120

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 2

ER -